Aclarion Welcomes Texas Back Institute to CLARITY Trial Network
Aclarion Welcomes Texas Back Institute to CLARITY Trial Network
In an exciting development for the medical community, Aclarion, Inc. has announced that the Texas Back Institute (TBI) will be joining the roster of trial sites for its CLARITY study. This partnership marks a significant step forward in spine care, as TBI is renowned for its innovative approaches in spine technology, science, and education.
Understanding the CLARITY Trial
The CLARITY trial aims to assess the effectiveness of Nociscan, Aclarion's advanced technology designed to improve surgical outcomes for patients suffering from chronic low back pain. This trial is characterized as a randomized clinical study that will showcase how Nociscan identifies pain sources using MR Spectroscopy and augmented intelligence. The objective is to ensure better treatment protocols and outcomes for patients.
Why Texas Back Institute?
With a strong reputation for excellence in research and clinical practice, the Texas Back Institute is an ideal site for this pivotal trial. Dr. Alexander Satin, a board-certified orthopedic spine surgeon and representative of TBI, expressed enthusiasm for collaborating on the CLARITY trial. TBI has a notable history of engaging in significant studies that enhance treatment outcomes in spinal care.
Collaboration with Esteemed Medical Institutions
The inclusion of TBI adds to an impressive list of previously announced trial sites that includes prestigious institutions like Johns Hopkins Medicine and Northwestern Medicine. Under the guidance of principal investigator Dr. Nicholas Theodore from Johns Hopkins, the CLARITY trial promises to contribute vital knowledge to the field of spinal surgery.
Details of the CLARITY Study
This multi-center, randomized trial is designed for patients with 1- or 2-level discogenic low back pain who are set to undergo surgical treatment. With an enrollment goal of 300 patients across various high-volume medical facilities, the trial utilizes a blinded and unblinded approach to determine the Nociscan’s impact on surgical outcomes.
Measuring Success in Patient Outcomes
The primary endpoint of this trial focuses on measuring changes in back pain using the visual analog scale (VAS) at a 12-month interval. Additional secondary endpoints will be collected, contributing to a comprehensive understanding of Nociscan’s effectiveness in clinical applications.
Ryan Bond, the Chief Strategy Officer at Aclarion, highlighted the esteemed reputation of the Texas Back Institute within the medical community, noting that their physicians routinely present groundbreaking research at significant spine society meetings. This partnership is anticipated to amplify the impact of the CLARITY trial.
The Global Challenge of Chronic Low Back Pain
Chronic low back pain is not just a local issue; it affects millions of individuals worldwide—approximately 266 million people are currently suffering from degenerative spine disease. Aclarion’s innovative Nociscan platform stands out as it represents the first evidence-backed solution that assists physicians in distinguishing between painful and non-painful discs in the lumbar spine. By quantifying chemical biomarkers related to disc pain, Nociscan aims to optimize surgical outcomes and improve patient lives.
Finding Nociscan Centers
Individuals seeking to explore Nociscan treatment options can easily find a certified center through the organization's online resources. Aclarion is committed to providing comprehensive support and information, ensuring patients have access to innovative treatment options that enhance their quality of life.
Frequently Asked Questions
What is the purpose of the CLARITY trial?
The CLARITY trial assesses the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain patients, employing innovative technologies.
Who is involved in the CLARITY trial?
The trial includes leading medical institutions like Texas Back Institute, Johns Hopkins Medicine, and Northwestern Medicine, with oversight from expert physicians.
How many patients will participate in the study?
There will be 300 patients enrolled in the CLARITY trial across multiple high-volume sites in the U.S.
What does Nociscan do?
Nociscan is a SaaS platform that helps physicians identify painful versus non-painful discs using Magnetic Resonance Spectroscopy (MRS).
How can I find a Nociscan center?
Aclarion provides a site map on their website to help patients locate certified Nociscan centers near them.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
